Breakthrough Treatments in Multiple Sclerosis

Multiple Sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system characterized by inflammation, demyelination, and neurodegeneration. Accurate diagnosis and timely initiation of disease-modifying therapy (DMT) are crucial to delaying progression and improving quality of life. This CME/CE course provides a deep dive into the most recent advancements in MS care, with a focus on diagnostic updates and emerging treatment options.

Participants will begin with an in-depth review of the 2024 McDonald Criteria for MS diagnosis. These criteria emphasize early and accurate diagnosis using a combination of clinical symptoms, MRI findings, and cerebrospinal fluid (CSF) analysis. The course discusses how to differentiate MS from mimicking conditions and how to apply the criteria in practice for both relapsing and progressive forms of MS.

A core element of this course is the application of shared decision-making in selecting and managing DMTs. Clinicians will explore key considerations such as disease activity, tolerability, comorbidities, and patient preferences. Emphasis is placed on collaborative goal-setting, side effect counseling, and monitoring strategies to optimize treatment success.

The course also highlights several breakthrough therapies currently in Phase 3 trials. These include novel oral, infusion, and injectable agents targeting B-cells, sphingosine-1-phosphate (S1P) receptors, and other immune pathways. Participants will gain insights into the mechanism of action, trial results, safety profiles, and potential placement in the evolving treatment algorithm.

Real-world case scenarios, recent trial data, and evidence-based guidelines are used to enhance clinical decision-making. Upon completion, learners will be equipped with the latest knowledge to diagnose MS confidently, engage patients in therapeutic planning, and evaluate emerging treatment options within a personalized care framework.

Educational Objectives

• Interpret the 2024 McDonald Criteria and apply them accurately for early diagnosis of Multiple Sclerosis.
• Implement shared decision-making when selecting and initiating disease-modifying therapies.
• Evaluate the safety, efficacy, and clinical role of new therapies currently in Phase 3 clinical trials for MS.

Who Should Do This Course?

This course is recommended for:

• Neurologists and MS Specialists involved in diagnosis, treatment, and follow-up care of MS patients.
• Nurse Practitioners and Physician Assistants managing long-term therapy and monitoring.
• Internal Medicine and Family Physicians conducting initial evaluations and referrals.
• Physical Medicine and Rehabilitation Providers addressing MS-related disability.
• Psychology and Pain Medicine professionals supporting MS patients with fatigue, depression, and chronic pain.

It is ideal for any clinician contributing to multidisciplinary MS care and seeking updated diagnostic and therapeutic insights.

Did You Know?

• Multiple Sclerosis affects nearly 1 million people in the U.S. alone. (National MS Society, 2023)
• Early diagnosis and DMT initiation can reduce relapse rates by up to 70%. (Neurology, 2022)
• More than 20 disease-modifying therapies are currently FDA-approved for MS. (FDA, 2023)
• Fatigue is reported by over 80% of MS patients and is often their most disabling symptom. (Journal of Neurology, 2021)
• Advances in MRI allow lesion detection before clinical symptoms appear in some MS cases. (Brain, 2020)